NCT00134251View on ClinicalTrials.gov

Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2005

Conditions
Parkinson's Disease
Interventions
DRUG

SLV308

Trial Locations (10)

Unknown

Site 16, Plovdiv

Site 11, Sofia

Site 12, Sofia

Site 13, Sofia

Site 14, Sofia

Site 15, Sofia

Site 21, Guardamangia

Site 31, Belgrade

Site 34, Belgrade

Site 33, Niš

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00134251 - Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease | Biotech Hunter | Biotech Hunter